Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24,220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.
Fonck M, Brunet R, Becouarn Y, Legoux JL, Dauba J, Cany L, Smith D, Auby D, Terrebonne E, Traissac L, Mertens C, Soubeyran P, Bellera C, Rainfray M, Mathoulin-Pélissier S. Fonck M, et al. Among authors: smith d. Clin Res Hepatol Gastroenterol. 2011 Dec;35(12):823-30. doi: 10.1016/j.clinre.2011.08.002. Epub 2011 Sep 8. Clin Res Hepatol Gastroenterol. 2011. PMID: 21907007 Clinical Trial.
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jové J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-Réglat A; ETNA study group. Rouyer M, et al. Among authors: smith d. Target Oncol. 2016 Feb;11(1):83-92. doi: 10.1007/s11523-015-0377-6. Target Oncol. 2016. PMID: 26298481
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
Rouyer M, Fourrier-Réglat A, Smith D, Becouarn Y, Guimbaud R, Tubiana-Mathieu N, Robinson P, Jové J, Grelaud A, Noize P, Moore N, Ravaud A. Rouyer M, et al. Among authors: smith d. J Geriatr Oncol. 2016 May;7(3):187-94. doi: 10.1016/j.jgo.2016.03.004. Epub 2016 Apr 14. J Geriatr Oncol. 2016. PMID: 27085302
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators; van Hazel G, Sharma RA. Wasan HS, et al. Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3. Lancet Oncol. 2017. PMID: 28781171 Free PMC article. Clinical Trial.
Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.
Tranquart F, Dujardin PA, Bouché O, Marcus C, Borg C, Manzoni P, Douillard JY, Labbe-Devilliers C, Terrebonne E, Smith D, Trillaud H, Capitain O, Aubé C, Spano JP, Lucidarme O, Ferru A, Tasu JP, Manfredi S, Bleuzen A, Léger J, Lecomte T. Tranquart F, et al. Among authors: smith d. Ultraschall Med. 2018 Oct;39(5):544-558. doi: 10.1055/s-0043-122497. Epub 2017 Dec 12. Ultraschall Med. 2018. PMID: 29232725 English.
24,220 results
You have reached the last available page of results. Please see the User Guide for more information.